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Immune reconstitution is critical for clinical outcome after allogeneic hematopoietic stem cell transplantation
(HSCT). To determine the impact of absolute lymphocyte count (ALC) recovery on clinical outcomes, we
conducted a retrospective study of 1109 adult patients who underwent a ﬁrst allogeneic HSCT from 2003
through 2009, excluding patients who died or relapsed before day 30. The median age was 51 years (range, 18
to 74) with 52% undergoing reduced-intensity conditioning and 48% undergoing myeloablative conditioning
HSCT with T cellereplete peripheral blood stem cells (93.7%) or marrow (6.4%) grafts. The median follow-up
time was 6 years. To determine the threshold value of ALC for survival, the entire cohort was randomly split
into a training set and a validation set in a 1:1 ratio, and then a restricted cubic spline smoothing method was
applied to obtain relative hazard estimates of the relationship between ALC at 1 month and log hazard of
progression-free survival (PFS). Based on this approach, ALC was categorized as .2  109 cells/L (low) or
>.2  109 cells/L. For patients with low ALC at 1, 2, or 3 months after HSCT, the overall survival (OS) (P 
.0001) and PFS (P  .0002) were signiﬁcantly lower and nonrelapse mortality (NRM) (P  .002) was signif-
icantly higher compared with patients with ALC > .2  109 cells/L at each time point. When patients who had
low ALC at 1, 2, or 3 months after HSCT were grouped together and compared, their outcomes were inferior to
those of patients who had ALC > .2  109 cells/L at 1, 2, and 3 months after HSCT: the 5-year OS for patients
with low ALC was 28% versus 46% for patients with ALC > .2  109 cells/L, P < .0001; the 5-year PFS was 21%
versus 39%, P < .0001, respectively and 5-year NRM was 40% versus 18%, P < .0001, respectively. This result
remained consistent when other prognostic factors, including occurrence of grade II to IV acute graft-versus-
host disease (GVHD), were adjusted for in multivariable Cox models stratiﬁed by conditioning intensity:
hazard ratio (HR) for OS: 1.52; P  .0001; for PFS: 1.42; P ¼ .0008; and for NRM: 2.4 P < .0001 for patients with
low ALC. Low ALC was not signiﬁcantly associated with relapse (HR, 1.01; P ¼ .92) in the multivariable model.
Low ALC early after HSCT is an independent risk factor for increased NRM and poor survival independent of
grade II to IV acute GVHD.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
Immune reconstitution is critical for clinical outcome
after allogeneic hematopoietic cell transplantation (HSCT).
Because donor lymphoid recovery is a robust surrogate ofdgments on page 879.
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ty for Blood and Marrow Transplantation.immune reconstitution, rapid lymphocyte recovery is asso-
ciated with a survival beneﬁt after allogeneic HSCT [1-10].
However, most of these studies are based on small cohort
sizes [4,7,10] and its effect on relapse and nonrelapse mor-
tality (NRM) is inconsistent. Several small studies [3-6]
found an association between low absolute lymphocyte
cell count (ALC) and relapse and NRM, whereas other
studies [7,10] found an association between low ALC and
NRM, but not with relapse. Furthermore, these studies
covered a wide range of post-transplantation assessment
H.T. Kim et al. / Biol Blood Marrow Transplant 21 (2015) 873e880874time points (days 21 to 100 after HSCT) and proposed
varying threshold values for deﬁning low ALC (.175  109
cells/L to .5  109 cells/L).
We have recently reported the impact of white blood cell
count (WBC) recovery early after allogeneic HSCT in a large
consecutive cohort of patients undergoing HSCT at our
institution [11], and we found a signiﬁcant association be-
tween abnormal WBC within 3 months of HSCT and survival
outcome. We now report the results of additional analyses




The study cohort, as previously reported [11], comprised 1109 consec-
utive adult patients who underwent ﬁrst peripheral blood or bone marrow
allogeneic HSCT with myeloablative (MAC) or reduced-intensity condition-
ing (RIC) at Dana Farber Cancer Institute/Brigham and Women’s Hospital
between 2003 and 2009. Patients receiving umbilical cord blood trans-
plantation, haplo-identical transplantation, or transplantation for benign
hematologic conditions were excluded. Patients who died or relapsed
within 1 month of HSCT were also excluded as ALC at 1 month could not be
assessed. All patients provided consent for use of protected health data for
research on a protocol approved by the institutional review board of the
Dana-Farber/Harvard Cancer Center. Demographic, clinical, and laboratory
data as well as HSCT outcomes were retrieved from our comprehensive
institutional transplantation database.
Attainment of ALC Data after HSCT
The ALC at or nearest (within 1 week) the set time points of the study
were retrieved from complete blood counts drawn as part of routine clinical
care after transplantation. In cases where multiple entries are present, the
ALC on the day closest to the set time point is used.
Transplantation
Patients underwent transplantation on a variety of investigational pro-
tocols and treatment plans. MAC regimens consisted mostly of cyclophos-
phamide (3600 mg/m2 or 120 mg/kg) plus total body irradiation (1400 cGy
in 7 fractions), or intravenous busulfan (12.8 mg/kg) plus cyclophosphamide
(3600 mg/m2). RIC regimens consisted primarily of ﬂudarabine (120mg/m2)
plus intravenous low-dose busulfan (3.2 to 6.4 mg/kg). A small number of
patients (<3%) received antithymocyte globulin (ATG) as part of condi-
tioning. Patients received bone marrow or ﬁlgrastim-mobilized peripheral
blood stem cells from HLA-matched or mismatched, related or unrelated
donors. Graft-versus-host disease (GVHD) prophylaxis consisted primarily
of a calcineurin inhibitor (cyclosporine or tacrolimus) combined with
methotrexate, with or without sirolimus (Table 1). Based on the clinical
protocols, ﬁlgrastim was usually started on day þ12 after MAC trans-
plantation or on day þ1 after RIC to hasten neutrophil engraftment, and it
was discontinuedwhen the absolute neutrophil counts was over 1000/mL for
2 consecutive days. Supportive care for all patients followed institutional
standards.
Chimerism Analysis
In patients undergoing RIC transplantation, day 30 total donor chime-
rismwas assessed from bone marrow aspirates and/or blood approximately
30 days after HSCT. Genotyping was determined by short tandem repeat
typing using the ABI Proﬁler Plus Kit (Applied Biosystems Inc., Foster City,
CA) and ABI 310 Genetic Analyzer (Applied Biosystems Inc., Foster City, CA).
“Informative” alleles speciﬁc to donor or recipient were used for chimerism
determination.
Endpoints and Statistical Analysis
The primary objective of the study was to assess the relationship of ALC
recovery at 1, 2, and 3 months after HSCT to survival outcome. To rule out the
direct inﬂuence of relapse on the ALC, a landmark analysis was performed at
1, 2, and 3 months after HSCT excluding relapse or death before each time
point. In fact, throughout the analysis, all ALC values thatweremeasured after
disease relapse within 3 months of HSCT were censored at each time point.
Deﬁnitions of overall survival (OS), progression-free survival (PFS), NRM, and
relapse are found in previously reports [11,12]. Stratiﬁed log-rank test by
conditioning intensity was used for comparisons of Kaplan-Meier curves.
Cumulative incidences for nonrelapse death and relapse with or without
death were estimated reﬂecting time to relapse and time to nonrelapse death
respectively as competing risks. Gray test [13] was used for comparison ofcumulative incidence curves. Multivariable proportional hazards models
stratiﬁed by conditioning intensity were constructed to examine the effect of
ALC after adjusting for other potential prognostic factors that are detailed in
Table 1, with WBC risk score after HSCT [11] and occurrence of grade II to IV
acute GVHD as a time-dependent variable. The proportional hazards
assumption for each variable was tested and interaction terms were exam-
ined. The linearity assumption for continuous variables was examined using
restricted cubic spline estimates of the relationship between the continuous
variable and log relative hazard [14], and the cutoff points of these variables
were based on the change of the log relative hazards. In particular, age was
dichotomized as40 versus<40 forMAC and60 versus<60 in RIC patients.
CD34 cells/kg were categorized as4106, 4 to 15106, and>15106 cells/
kg. For factors associated with low ALC, multivariable logistic regression
analysis was utilized using a backward elimination approach. All P-values are
2-sided. Considering multiple comparisons, the signiﬁcance level was set to
.01 for the primary hypothesis but to .05 for secondary analyses. All calcula-
tions were done using SAS 9.3 (SAS Institute Inc, Cary, NC), and R version
2.13.2 (the CRAN project).
RESULTS
Patient Characteristics
The baseline characteristics of the 1109 patients are
shown in Table 1. The median age was 51 years (range, 18 to
74). The median follow-up time among surviving patients
was 6 years (range, 2.5 to 9.8). Fifty-two percent of patients
received RIC and 48% received MAC. Seventy-seven percent
of patients were Eastern Cooperative Oncology Group
(ECOG) performance status 0 or 1 at baseline. Forty-one
percent of patients underwent transplantation from HLA-
matched related donors, 51% underwent transplantation
from HLA-matched unrelated donors, and 8.5% received
HLA-mismatched transplantation. Ninety-four percent of
patients received stem cells from granulocyte colonye
stimulating factoremobilized peripheral blood. The distri-
bution of disease risk index, which was created based on
disease and disease status at transplantation [12], was 16%
for low, 53% intermediate, 27% for high, and 3.3% for very
high risk.
ALC after HSCT and Threshold Value
The distribution of ALC (excluding values after disease
relapse) at 1, 2, and 3 months after HSCT is shown in
Figure 1A. The median ALC at these 3 time points was be-
tween .64 and .7  109 cells/L (interquartile range, .41 to 1.1),
and 32% to 36% of patients had an ALC  .5  109 cells/L
during this period. Because the lower cutoff value for normal
reference ALC (.5109 cells/L) may not be the most clinically
relevant threshold in this patient population, we randomly
split the entire cohort into a training set and a validation set
in a 1:1 ratio stratiﬁed by conditioning intensity, and thenwe
applied a restricted cubic spline smoothing method [14] to
obtain relative hazard estimates of the relationship between
ALC at 1 month and log hazard of PFS.
The restricted cubic spline curves suggest a sharp
decrease in relative hazard initially between 0 and .5  109
cells/L, locating the ﬁrst knot around .2  109 cells/L, and
then a plateau (Figure S1). We then calculated hazard ratios
(HR) of PFS by intervals of 0 to .2, .2 to .3, .3 to .4, .4 to
.5, .5 to 2.6 (normal range, reference group), and >2.6 
109 cells/L (Figure 1B). In Figure 1B, the HR for the interval
0 to .2  109 cells/L was signiﬁcantly higher (P < .001) than
the reference group in both the training and validation sets.
Although HRs for intervals of .2 to.3, .3 to .4, and .4 to .5
were higher than the reference group, none of these intervals
was signiﬁcantly high. To facilitate the practical use of ALC
data, we thus propose the ALC level by 0 to .2  109 cells/L
versus >.2  109 cells/L. Using this cutoff value, 7.5%, 6.4%,
and 5.5% of patients had low ALC at 1, 2, or 3 months,
Table 1
Baseline Characteristics
Characteristic All ALC* > .2 ALC*  .2 P Value
(N ¼ 1109) (n ¼ 957) (n ¼ 152)
N % N % N %
Age, median (range), yr 51 (18-74) 51 (18-74) 52 (19-70) .11
Patient sex .09
Male 658 59.3 558 58.3 100 65.8
Female 451 40.7 399 41.7 52 34.2
Donor sex .09
Male 639 57.6 561 58.6 78 51.3
Female 470 42.4 396 41.4 74 48.7
Patient-donor sex .08
Female-female 205 18.5 175 18.3 30 19.7
Female-male 246 22.2 224 23.4 22 14.5
Male-female 265 23.9 221 23.1 44 28.9
Male-male 393 35.4 337 35.2 56 36.8
ECOG performance status .09
0 374 33.7 333 34.8 41 27
1 480 43.3 415 43.4 65 42.8
2-3 99 8.9 81 8.5 18 11.8
Unknown 156 14.1 128 13.4 28 18.4
Disease .09
AML 404 36.4 354 37 50 32.9
ALL 100 9 91 9.5 9 5.9
CLL 102 9.2 84 8.8 18 11.8
CML 78 7 68 7.1 10 6.6
Hodgkin lymphoma 50 4.5 45 4.7 5 3.3
Multiple myeloma 35 3.2 30 3.1 5 3.3
MDS 130 11.7 101 10.6 29 19.1
Myeloproliferative neoplasms 25 2.4 20 2.1 5 4
Non-Hodgkin lymphoma 180 16.2 160 16.7 20 13.2
Other acute leukemia 4 .4 4 .4
HLA type .001
Matched/unrelated 565 50.9 488 51 77 50.7
Matched/related 450 40.6 400 41.8 50 32.9
Mismatched/unrelated 86 7.8 63 6.6 23 15.1
Mismatched/related 8 .7 6 .6 2 1.3
Graft source .01
Bone marrow 70 6.4 53 5.5 17 11.2
PBSC 1039 93.7 904 94.5 135 88.8
Conditioning intensity .29
MAC 528 47.6 462 48.3 66 43.4
RIC 581 52.4 495 51.7 86 56.6
ATG usey .01
Yes 33 3 23 2.4 10 6.6
Disease risk index [12] .96
0: Low 177 16 155 16.2 22 14.5
1: Intermediate 591 53.3 508 53.1 83 54.6
2: High 304 27.4 262 27.4 42 27.6
3: Very high 37 3.3 32 3.3 5 3.3
Patient or donor CMV seropositivity .47
No 421 38 359 37.5 62 40.8
Yes 688 62 598 62.5 90 59.2
aGVHD prophylaxis .009
CI þ sirolimus 697 62.8 609 63.7 88 57.9
CI þ other 376 33.9 323 33.6 53 35
Ex vivo TCD/other 36 3.1 25 2.5 11 7.3
CD34 (106 cells/kg)
0-5 266 24 213 22.3 53 34.9 .005
5-10 505 45.5 444 46.4 61 40.1
10-15 206 18.6 181 18.9 25 16.4
>15 127 11.5 116 12.1 11 7.2
Unknown 5 .5 3 .3 2 1.3
Median (range) 7.8 (.3-47.7) 8 (.3, 47.7) 6.7 (.8, 25) .0009
Day 30 chimerismz, median (range) 95 (0-100) 96 (0-100) .92
No. of missing chimerism 6 1.2 2 2.3 .34
AML indicates acute myeloid leukemia; ALL, acute lymphoblastic leukemia; CLL, chronic lymphoblastic leukemia; CML, chronic myeloid leukemia; MDS,
myelodysplastic syndrome; PBSC, peripheral blood stem cells; CMV, cytomegalovirus; aGVHD, acute graft-versus-host disease; CI, calcineurin inhibitor; TCD, T
cell depletion.
* ALC > .2  109 cells/L at 1, 2, and 3 months after HSCT; ALC  .2  109 cells/L at 1, 2, or 3 months after HSCT.
y As part of conditioning.
z Patients with reduced-intensity conditioning only.
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Figure 1. (A) Frequencies of ALC at 1, 2, and 3 months after HCT. Patients who
relapsed before 2 or 3 months after HCT were excluded at 2 and 3 month
frequencies, respectively. Median ALC level was .64  109 cells/L (interquartile
range [IQ]: .41 to .99 109 cells/L), .67  109 cells/L (IQ: .41 to 1.04  109 cells/
L), .7  109 cells/L (IQ: .44 to 1.10  109 cells/L) at 1, 2, and 3 months after HCT,
respectively. (B) Hazard ratios of D30 ALC level (0- .2, .2- .3, .3- .4, .4- .5,
.5- 2.6, > 2.6) relative to the normal range (.5-2.6  109 cells/L, reference
group) from Cox proportional hazards model using the training and validation
set.
H.T. Kim et al. / Biol Blood Marrow Transplant 21 (2015) 873e880876respectively, after HSCT. Overall, 14% of patients had low ALC
at some point during the ﬁrst 3 months of HSCT.
Factors Associated with Low ALC
Univariable and multivariable analyses were performed
to assess baseline factors that are associated with low ALC at
1, 2, or 3 months after HSCT. In univariable analysis, signiﬁ-
cant risk factors for developing low ALC were mismatched
HLA type (P ¼ .001), bone marrow graft source (P ¼ .01),
nonsirolimus-based prophylaxis (P ¼ .009), low CD34 cells
infused (P ¼ .005 for 5-unit decrease), and ATG use as part of
conditioning (P ¼ .01) (Table 1). However, only mismatched
HLA type (odds ratio [OR], 3.09; 95% conﬁdence interval [CI],
1.78 to 5.35; P < .0001), low CD34 cells infused (OR, 1.34 for a
5-unit decrease; 95% CI, 1.11 to 1.63; P ¼ .003), and ATG use
(OR, 3.22; 95% CI, 1.48 to 7.01; P ¼ .003) were signiﬁcant in
multivariable analysis (data not shown).
Impact of ALC on Survival Outcomes
Regardless of the time point (1, 2, or 3months after HSCT),
low ALC was associated with inferior OS, PFS, and NRM but
not with relapse. Five-year OS was 30% versus 45%, 28%
versus 49%, and 27% versus 53% for patients with low ALC
versus ALC> .2  109 cells/L at 1, 2, and 3 months after HSCT,respectively (P  .0001 for all comparisons). (Figure 2A-C,
Table S1). Five-year PFS was 19% versus 38% (P < .0001), 25%
versus 41% (P ¼ .0002), and 22% versus 45% (P < .0001) for
patients with low ALC versus ALC > .2  109 cells/L at 1, 2,
and 3 months after HSCT, respectively. (Figure S2 A-C,
Table S1). Five-year cumulative incidence of NRM was 33%
versus 20% (P ¼ .002), 44% versus 19% (P < .0001), and 41%
versus 18% (P < .0001) for patients with low ALC versus ALC
> .2  109 cells/L at 1, 2, and 3 months after HSCT, respec-
tively. (Table S1, Figure 2D-F).
Because the landmark analysis for low ALC at 2 or 3
months after HSCT had equally poor outcome as for those
whose ALC were low at 1 month after HSCT, we combined
patients who had low ALC at 1,2, or 3 months after HSCT and
compared themwith patients with ALC> .2 109 cells/L at 1,
2, and 3months after HSCT. Comparedwith thosewith ALC>
.2 109 cells/L at all 3 time points, patients with low ALC had
poor OS (5-year OS: 28% versus 46%, P < .0001), PFS (5-year
PFS: 21% versus 39%, P< .0001), and NRM (5-year cumulative
incidence of NRM: 40% versus 18%, P < .0001) but no differ-
ence in relapse (5-year cumulative incidence of relapse: 40%
versus 43%, P ¼ .29) (Table 2, Figure 3A-C). This result
remained consistent when other prognostic factors were
adjusted for in multivariable Cox models stratiﬁed by con-
ditioning intensity: HR, 1.53 for OS; P ¼ .0001; HR for PFS,
1.43; P ¼ .0009; HR for NRM, 2.34; P < .0001 for low ALC
within 3months of HSCTcomparedwith ALC> .2 109 cells/
L during 3 months of HSCT (Table 2, Table S2). Furthermore,
to rule out the impact of corticosteroid use for patients with
acute GVHD on ALC, we repeated the multivariable analysis
excluding patients who developed grade II to IV acute GVHD
and the result remained unchanged: HR, 1.85; 95% CI, 1.39 to
2.46; P< .0001 for OS; HR,1.62; 95% CI, 1.23 to 2.13; P¼ .0006
for PFS; HR, 3.07; 95% CI, 1.89 to 4.98; P < .0001 for NRM
(data not shown).
Impact of Comorbidities
Because low ALC is associated with NRM, we investigated
the impact of low ALC on NRM in the presence of comor-
bidities. Of 1109 patients, we were able to calculate an he-
matopoietic cell transplantation speciﬁcecomorbidity index
(HCT-CI) [15] for 625 patients (56%) and the median score
was 1 (range, 0 to 9). We found that there is no correlation
between low ALC at 1, 2, or 3 months after HSCT and HCT-CI
(P ¼ .31). When we included HCT-CI in the multivariable
models for patients with HCT-CI data available, low ALC
retained its signiﬁcance for OS (HR, 1.97; 95% CI, 1.45 to 2.66;
P < .0001), PFS (HR, 1.64; 95% CI, 1.22 to 2.21; P ¼ .001), and
NRM (HR, 2.35; 95% CI, 1.45 to 3.81; P¼ .0005). HCT-CI of 1 to
2 compared with HCT-CI of 0 was not signiﬁcant for OS (HR,
1.24; 95% CI, .95 to 1.61; P ¼ .11), PFS (HR, 1.1; 95% CI, .86 to
1.40; P ¼ .45), NRM (HR, 1.35; 95% CI, .88 to 2.06; P¼ .17), and
relapse (HR, .97; 95% CI, .71 to 1.31; P ¼ .82). However, high
HCT-CI (3) was signiﬁcant for OS (HR, 1.66; 95% CI, 1.26 to
2.19; P ¼ .0004) and PFS (HR, 1.33; 95% CI, 1.02 to 1.73; P ¼
.03). For NRM (HR, 1.49; 95% CI, .93 to 2.38; P ¼ .10) and
relapse (HR, 1.20; 95% CI, .87 to 1.66; P ¼ .26), high HCT-CI
(3) did not reach statistical signiﬁcance.
Landmark Analysis at 100 Days after HSCT
To conﬁrm that the low ALC within 3 months of HSCT was
not just a predictor of imminent NRM, but that it also has
prognostic signiﬁcance for survival outcomes, we performed
a landmark analysis restricted to patients whowere alive and
relapse-free beyond 100 days of HSCT. The results from
Figure 2. Overall survival by ALC level at 1 month (A), 2 months (B), and 3 months (C) after HCT. Cumulative incidence of NRM at 1 month (D), 2 months (E), and 3
months (F) after HCT.
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year OS was 37% versus 56% (P < .0001), 5-year PFS was 28%
versus 48% (P < .0001), 5-year cumulative incidence of NRM
was 33% versus 18% (P ¼ .0002), and 5-year cumulative
incidence of relapsewas 34% versus 39% (P¼ .45) for patients
with low ALC versus ALC > .2  109 cells/L, respectively
(Table 3, Figure 3D-F).
Because low ALC within 3 months of HCT is associated
with an increased NRM later, we investigated cause of death
among patients who died after day 100 after HSCT using the
hierarchical scheme similar to that proposed by Copelan
et al. [16]. The main causes of death were disease relapseTable 2
Summary of Outcomes
Outcome Univariable Analysis
ALC  .2y ALC > .2z
5 Yr % (95% CI) 5 Yr % (95% CI)
n 152 957
OS 28 (21-35) 46 (43-49)
PFS 21 (15-27) 39 (36-42)
CI of relapse 40 (32-47) 43 (40-46)
CI of NRM 40 (32-48) 18 (16-21)
CI indicates cumulative incidence.
* Cause-speciﬁc hazard, stratiﬁed by conditioning intensity. The model includes
risk index, year of HSCT, CD34 cell dose, ECOG status, graft source, day 30 donor ch
HSCT, and WBC risk group. See Table S2 for full information.
y ALC  .2  109 cells/L any time within 3 months of HCT.
z ALC > .2  109 cells/L at 1, 2, and 3 months of HSCT.
x HR of ALC  .2  109 cells/L any time within 3 months of HCT over ALC > .2 (36% versus 50.4% for patients with low ALC and ALC > .2 
109 cells/L, respectively), GVHD (21.3% versus 11.2% for pa-
tients with low ALC and ALC > .2  109 cells/L, respectively),
infection (18.7% versus 12.3% for patients with low ALC and
ALC > .2  109 cells/L, respectively), and organ failure (14.7%
versus 9.3% for patients with low ALC and ALC > .2  109
cells/L, respectively) (P ¼ .018) (Figure 4A,B).
ALC versus WBC
To investigate the relationship between ALC and WBC
recovery after HSCT, we ﬁrst assessed correlation between
ALC and WBC at 1, 2, and 3 months after HSCT (Figure S3).Multivariable Analysis*
P Value HRx (95% CI) P Value
<.0001 1.53 (1.23-1.9) .0001
<.0001 1.43 (1.16-1.76) .0009
.29 1.04 (.78-1.38) .81
<.0001 2.34 (1.7-3.22) <.0001
age, patient-donor sex, HLA type, patient-donor CMV seropositivity, disease
imerism for RIC only, grade II to IV aGVHD, ATG use, ALC within 3 months of
109 cells/L at 1, 2, and 3 months of HSCT.
Table 3
Summary of Outcome (Landmark Analysis at Day 100 after HSCT)
Outcome Univariable Analysis Multivariable Analysis*
ALC  .2y ALC > .2z P Value HRx (95% CI) P Value
5 Yr % (95% CI) 5 Yr % (95% CI)
n 111 774
OS 37 (28-46) 56 (52-60) <.0001 1.61 (1.23-2.1) .0005
PFS 28 (20-37) 48 (44-51) <.0001 1.48 (1.15-1.92) .0025
CI of relapse 39 (30-48) 34 (31-38) .45 1.25 (.89-1.76) .20
CI of NRM 33 (24-42) 18 (15-21) .0002 1.91 (1.29-2.83) .001
* Cause-speciﬁc hazard, stratiﬁed by conditioning intensity. The model includes age, patient-donor sex, HLA type, patient-donor CMV seropositivity, disease
risk index, year of HSCT, CD34 cell dose, ECOG status, graft source, day 30 donor chimerism for RIC only, grade II to IV aGVHD, ATG use, ALC within 3 months of
HSCT, and WBC risk group. See Table S2 for full information.
y ALC  .2  109 cells/L any time within 3 months of HCT.
z ALC > .2  109 cells/L at 1, 2, and 3 months of HSCT.
x HR of ALC  .2  109 cells/L any time within 3 months of HCT over ALC > .2  109 cells/L at 1, 2, and 3 months of HSCT.
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that a weak correlation between the 2 metrics. Further
investigation revealed that high WBC does not necessarily
coincide with high ALC; many patients with normal ALC (ie,
.5 to 2.6  109 cells/L) had high WBC and vice versa.
Because of this reason, when our previously published WBC
risk score [11] was added to the multivariable model, the
predictability of the model was improved: the multivariable
C-index [14], the probability of concordance between pre-
dicted and observed survival among all usable pairs, for OS
was . 673 with ALC alone but .688 with both ALC and the
WBC risk score in the model. The multivariable C-index forFigure 3. Overall survival (A), PFS (B), cumulative incidence of NRM (C) by ALC level
overall survival (D), PFS (E), and cumulative incidence of NRM (F).NRMwas .712 with ALC alone but .739 with both ALC and the
WBC risk score in the model.
Factors Associated with Relapse and NRM
Based on the multivariable analysis, factors that were
associated with high NRM were low ALC, low or high WBC,
advanced age, unrelated or mismatched HLA type, poor
ECOG performance status, and incidence of grade II to IV
acute GVHD. Factors that were associated with high relapse
were highWBC, disease risk index [12], matched related HLA
type, poor ECOG performance status, and day 30 total donor
cell chimerism<90% in RIC. Incidence of grade II to IV aGVHDat any time within 3 months of HCT. Landmark analysis at day 100 after HCT:
Figure 4. Landmark analysis at day 100 after HSCT. (A) Pie chart of cause of death for patients with ALC  .2  109 cells/L at 1, 2, or 3 months after HSCT. (B) Pie chart
of cause of death for patients with ALC > .2  109 cells/L at 1, 2, and 3 months of HSCT. Unk, unknown due to the loss of follow up; Sec Ca, secondary cancer.
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the increased risk of the competing event, NRM. (Table S2).DISCUSSION
NRM and relapse remain to be the major reasons of
treatment failure after HSCT. In particular, NRM is a major
determinant for long-term survival, especially after MAC
HSCT. NRM after HSCT may result from early or late organ
toxicities from the conditioning regimen, GVHD, and/or
opportunistic infections. In our current study, we have found
that the presence of a low ALC at 1, 2, or 3 months after HSCT
is associated with a signiﬁcant increase in NRM and poor
long-term survival, with a majority of deaths resulting from
GVHD and infections. Importantly, low ALC is not associated
with increased relapse, and it predicts for poor NRM inde-
pendent of grade II to IV acute GVHD.
To our knowledge, this is the largest cohort study to date
assessing the impact of ALC early after HSCT. Although pre-
vious publications have demonstrated an association be-
tween poor ALC recovery and clinical outcomes after HSCT
[1-10], these studies are mostly small and limited to
myeloid disease or acute leukemias. Consistent with these
previous reports, we have found that low ALC in the ﬁrst 3
months after HSCT is a signiﬁcant predictor of poor OS, PFS,
and NRM. In contrast to previous studies, however, our study
includes a much larger population of patients with a wide
spectrum of hematologic malignancies who underwent
HSCT using homogeneous and standard MAC and RIC (low
dose busulfan/ﬂudarabine) regimens considered standard in
most transplantation centers. These attributes should render
our study results more generalizable to the “real world”
peripheral blood stem cell/bone marrow HSCT setting.
Based on our large cohort, we have identiﬁed an ALC
threshold value of .2  109 cells/L as the most predictive of
outcomes in our models. Importantly, this threshold value is
prognostic across different diseases.
The effect of low ALC is stronger in MAC HSCT than in RIC.
The reasons for stronger association in MAC HSC are unclear,
but it is possible that the ALC early after MAC HSCT is more
useful because it reﬂects mainly donor lymphocyte recon-
stitution, whereas in RIC HSCT, the ALC in the ﬁrst 3 months
very likely reﬂect a mixed chimera of both donor and host
lymphocyte populations. In the absence of lymphocyte
chimerism data, we cannot dissociate the potentiallyopposing effects of donor versus host derived ALC on out-
comes after RIC HSCT.
Our study is limited by the fact that it is based on
transplantations performed at a single institution, and as
such, could be confounded by institutional biases and
practices. It is also subject to the inherent ﬂaws of any
retrospective study design. We do believe, however, that
these limitations are mitigated to some degree by the large
size of the cohort, the homogeneity of conditioning regi-
mens used, and the completeness of data at the different
time points. Another limitation of the study is that because
we studied ALC at ﬁxed time points at 1, 2, and 3 months
after HSCT, it is not feasible to investigate whether concur-
rent or prior acute GVHD is a factor for developing low ALC
or whether low ALC proceeds to the development of acute
GVHD. To address this question, a more detailed prospective
study is needed. Regarding comorbidity, we were able to
calculate an HCT-CI [15] for only 56% of patients because
HCT-CI data were not collected before 2006. As such, the
assessment of its full impact on NRM is limited, although
the hazard ratio of patients with missing HCT-CI relative to
those with HCT-CI is 1.1 (P ¼ .29), indicating that the subset
can be viewed as a random subset.
In summary, our ﬁnding suggests that the ALC at 1, 2, and
3 months after HSCT may have signiﬁcant prognostic im-
plications. Low ALC early after HSCT is an independent risk
factor for increased NRM and poor survival independent of
grade II to IV acute GVHD. These ﬁndings suggest that ALC
could potentially be used as a readily available metric for
identifying patients within 100 days of HSCT who are at
increased risk for NRM, who could thus be observed more
closely for infections, GVHD, and other transplantation
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